Engineered extracellular vesicles for bone therapy

Extracellular vesicles, which are secreted by living cells and play a critical role in cellular communication, have emerged as a promising cell-free strategy in the treatment of many diseases. Recently, EVs are con-sidered excellent delivery systems for various therapeutic agents, including nucleic acids, proteins, drugs, and nanomaterials, owing to their superior physiochemical stability and biocompatibility. Yet, drawbacks such as the the uncertain distribution, unfavorable therapeutic efficiency and low yields are still the pri-mary obstacles that hinder the application of EVs in the clinical. An increasing number of studies show that EVs can be internally engineered via cargo loading and externally engineered via surface modification to track their distributions, obtain scalable production and improve bone-targeting capacity for bone therapy. Herein, we provide a brief overview of the present applications and therapeutic mechanism of EVs for bone-related diseases. Thereafter, a comprehensive overview of methodological advances made recently in in-ternally and externally engineering EVs is presented. Moreover, the potential applications of modified EVs are discussed by presenting prominent examples for the treatment of osteoarthritis, osteoporosis, and bone fracture and defects, as well as the prospective engineering approaches to address these issues.(c) 2022 Elsevier Ltd. All rights reserved.

Automated summary

Extracellular vesicles (EVs) have emerged as a promising cell-free strategy in the treatment of bone-related diseases. However, challenges such as uncertain distribution, unfavorable therapeutic efficiency, and low yields hinder their clinical application. Internal and external engineering of EVs can address these issues and improve their bone-targeting capacity.